Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other


Tags
Appointed director

BIOMERICA INC (BMRA) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/12/2023 10-Q Quarterly Report for the period ended August 31, 2023
10/02/2023 EFFECT Form EFFECT - Notice of Effectiveness:
09/27/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
08/25/2023 10-K Annual Report for the period ended May 31, 2023
08/18/2023 3 Form 3 - Initial statement of beneficial ownership of securities:
07/26/2023 8-K Quarterly results
07/03/2023 5 BARBIERI ALLEN (Vice Chairman) has filed a Form 5 on BIOMERICA INC
05/26/2023 4 Irani Zackary S. (CEO) has filed a Form 4 on BIOMERICA INC
Txns: Bought 500 shares @ $1.61, valued at $805
Bought 200 shares @ $1.55, valued at $310
05/12/2023 4 Irani Zackary S. (CEO) has filed a Form 4 on BIOMERICA INC
Txns: Bought 1,700 shares @ $1.17, valued at $2k
05/10/2023 4 Irani Zackary S. (CEO) has filed a Form 4 on BIOMERICA INC
Txns: Bought 300 shares @ $1.39, valued at $417
05/05/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
05/01/2023 4 Irani Zackary S. (CEO) has filed a Form 4 on BIOMERICA INC
Txns: Bought 2,600 shares @ $1.31, valued at $3.4k
Bought 1,800 shares @ $1.34, valued at $2.4k
04/27/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
04/25/2023 8-K Quarterly results
04/14/2023 10-Q Quarterly Report for the period ended February 28, 2023
03/09/2023 3 Lu Gary (CFO) has filed a Form 3 on BIOMERICA INC
03/07/2023 8-K Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits  Inte...
Docs: "BIOMERICA, INC. UNDERWRITING AGREEMENT",
"Letter re: Shares of Common Stock of Biomerica, Inc.",
"Biomerica Announces Proposed Underwritten Public Offering of Common Stock",
"Biomerica Announces Pricing of $8 Million Underwritten Public Offering of Common Stock",
"Biomerica Announces Closing of $8 Million Underwritten Public Offering of Common Stock IRVINE, Calif., March 07, 2023-Biomerica, Inc. , a global provider of advanced medical products, announced today the closing of its previously announced underwritten public offering of an aggregate of 3,333,333 shares of its common stock, par value $0.08 per share, at a price to the public of $2.40 per sharefor total gross proceeds of $8 million, before deducting underwriting discounts and commissions and other offering-related expenses payable by Biomerica. All of the shares of common stock sold in the offering were offered by Biomerica. Craig-Hallum Capital Group LLC acted as sole managing underwriter in connection with the offering. Biomerica intends to use the net proceeds of the offering for general..."
03/02/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
03/02/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
03/02/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
02/14/2023 SC 13G/A Granahan Investment Management, LLC reports a 8.4% stake in BIOMERICA, INC.
02/07/2023 8-K Investor presentation
Docs: "FORM 8-K"
01/31/2023 4 BARBIERI ALLEN (Executive Vice Chairman) has filed a Form 4 on BIOMERICA INC
Txns: Bought 1,538 shares @ $2.94, valued at $4.5k
01/30/2023 4 Coste Catherine (Director) has filed a Form 4 on BIOMERICA INC
Txns: Bought 2,190 shares @ $2.96, valued at $6.5k
01/26/2023 4 Irani Zackary S. (CEO) has filed a Form 4 on BIOMERICA INC
Txns: Bought 1,800 shares @ $2.85, valued at $5.1k
01/25/2023 4 Irani Zackary S. (CEO) has filed a Form 4 on BIOMERICA INC
Txns: Bought 2,000 shares @ $2.81, valued at $5.6k
01/13/2023 10-Q Quarterly Report for the period ended November 30, 2022
12/29/2022 8-K/A Quarterly results
12/16/2022 8-K Quarterly results
12/16/2022 8-K Quarterly results
12/09/2022 8-K Quarterly results
12/09/2022 8-K Quarterly results
11/14/2022 8-K Quarterly results
10/13/2022 10-Q Quarterly Report for the period ended August 31, 2022
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy